Short- and long-term motor outcome of STN-DBS in Parkinson's Disease: focus on sex differences

Neurol Sci. 2022 Mar;43(3):1769-1781. doi: 10.1007/s10072-021-05564-w. Epub 2021 Sep 9.

Abstract

Introduction: Subthalamic nucleus deep brain stimulation (STN-DBS) is an established treatment for patients with Parkinson's disease (PD) with motor complications; the contribution of sex in determining the outcome is still not understood.

Methods: We included 107 patients (71 males) with PD consecutively implanted with STN-DBS at our center. We reviewed patient charts from our database and retrospectively collected demographical and clinical data at baseline and at three follow-up visits (1, 5 and 10 years).

Results: We found a long-lasting effect of DBS on motor complications, despite a progressive worsening of motor performances in the ON medication condition. Bradykinesia and non-dopaminergic features seem to be the major determinant of this progression. Conversely to males, females showed a trend towards worsening in bradykinesia already at 1-year follow-up and poorer scores in non-dopaminergic features at 10-year follow-up. Levodopa Equivalent Daily Dose (LEDD) was significantly reduced after surgery compared to baseline values; however, while in males LEDD remained significantly lower than baseline even 10 years after surgery, in females LEDD returned at baseline values. Males showed a sustained effect on dyskinesias, but this benefit was less clear in females; the total electrical energy delivered was consistently lower in females compared to males. The profile of adverse events did not appear to be influenced by sex.

Conclusion: Our data suggest that there are no major differences on the motor effect of STN-DBS between males and females. However, there may be some slight differences that should be specifically investigated in the future and that may influence therapeutic decisions in the chronic follow-up.

Keywords: DBS; Gender; Parkinson’s disease; Sex differences.

MeSH terms

  • Deep Brain Stimulation*
  • Female
  • Humans
  • Levodopa / therapeutic use
  • Male
  • Parkinson Disease* / drug therapy
  • Retrospective Studies
  • Sex Characteristics
  • Treatment Outcome

Substances

  • Levodopa